Hat mitgewirkt an:
-
Mechanistic analysis of Angiopoietin-2 targeting in advanced mouse models of metastasis
-
Preclinical validation of a novel metastasis‐inhibiting Tie1 function‐blocking antibody
-
Timed Ang2-targeted therapy identifies the Angiopoietin–tie pathway as key regulator of fatal lymphogenous metastasis
-
Primary tumor–derived systemic nANGPTL4 inhibits metastasis